title: Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia.
abstract: BACKGROUND
  Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with a high burden in West Africa. Data evaluating aetiological differences in HCC presentation from this region are limited.
  
  
  OBJECTIVE
  The aim of this study was to describe the demographical, clinical and pathological characteristics of HCC by aetiology (hepatitis B or C infection, aflatoxin associated).
  
  
  METHODS
  One hundred and ninty-three cases of HCC diagnosed between 1997 and 2001 in The Gambia were analysed. Characteristics were compared by aetiology using χ(2)-tests, student t-test and Wilcoxon's rank sum tests as appropriate.
  
  
  RESULTS
  The prevalence of hepatitis B surface antigen, hepatitis C antibody and aflatoxin-associated 249(ser) TP53 mutations among HCC patients was 60, 20 and 38% respectively. The typical HCC patient was a 49-year-old male positive for hepatitis B surface antigen presenting with hepatomegaly (93%), abdominal pain (94%) and weight loss (95%) 8 weeks after symptom onset. Most patients had multifocal lesions with background cirrhosis. The median largest tumour was 10.3 cm and the median α-fetoprotein level was 500 ng/ml. Eighty-four per cent of patients had advanced HCC (patients not meeting the Milan criteria) at presentation.
  
  
  CONCLUSIONS
  Irrespective of aetiological agent, HCC among West Africans presents at very advanced stages. Few clinical or pathological differences exist by aetiology. More studies are needed to understand the mechanisms of hepatocarcinogenesis among these patients as well as identify high-risk populations in which early detection through screening will be beneficial.
authors.affiliation: Department of Surgery, Geisinger Medical Center, Danville, PA 17822, USA. nsykumoh@yahoo.com
authors.forename: Nsikak J
authors.initials: NJ
authors.lastname: Umoh
authors.forename: Olufunmilayo A
authors.initials: OA
authors.lastname: Lesi
authors.forename: Maimuna
authors.initials: M
authors.lastname: Mendy
authors.forename: Ebrima
authors.initials: E
authors.lastname: Bah
authors.forename: Aliu
authors.initials: A
authors.lastname: Akano
authors.forename: Hilton
authors.initials: H
authors.lastname: Whittle
authors.forename: Pierre
authors.initials: P
authors.lastname: Hainaut
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Kirk
mesh_terms: D000328:Adult; D016604:Aflatoxin B1 / Q000633:toxicity*; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000209:etiology* / Q000473:pathology; D003710:Demography; D005260:Female; D005714:Gambia / Q000453:epidemiology; D006509:Hepatitis B / Q000150:complications* / Q000453:epidemiology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology; D018936:Hepatitis C Antigens / Q000032:analysis; D006801:Humans; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000209:etiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense / Q000235:genetics; D015995:Prevalence; D012737:Sex Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
chemical_list: D006514:Hepatitis B Surface Antigens; D018936:Hepatitis C Antigens; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D016604:Aflatoxin B1